Lim SY, Klein C. Parkinson’s disease is predominantly a genetic disease. J Parkinsons Dis. 2024;14(3):467–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherian A, Puthenveedu KD, Vijayaraghavan A. Parkinson’s disease—genetic cause. Curr Opin Neurol. 2023;36(4):292–301.

Article  PubMed  Google Scholar 

Jia F, Fellner A, Kumar KR. Monogenic Parkinson’s disease: genotype, phenotype, pathophysiology, and genetic testing. Genes. 2022. https://doi.org/10.3390/genes13030471.

Article  PubMed  PubMed Central  Google Scholar 

Lange LM, Cerquera-Cleves C, Schipper M, Panagiotaropoulou G, Braun A, Kraft J, et al. Prioritizing Parkinson’s disease risk genes in genome-wide association loci. NPJ Parkinsons Dis. 2025;11(1):77.

Article  PubMed  PubMed Central  Google Scholar 

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.

Article  CAS  PubMed  Google Scholar 

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–7.

Article  CAS  PubMed  Google Scholar 

Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, Brown MF, et al. The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys J. 2010;99(7):2116–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vekrellis K, Emmanouilidou E, Xilouri M, Stefanis L. alpha-Synuclein in Parkinson’s disease: 12 years later. Cold Spring Harb Perspect Med. 2024;14(11):a041645.

Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004;364(9440):1167–9.

Article  CAS  PubMed  Google Scholar 

Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302(5646):841.

Article  CAS  PubMed  Google Scholar 

Pihlstrom L, Blauwendraat C, Cappelletti C, Berge-Seidl V, Langmyhr M, Henriksen SP, et al. A comprehensive analysis of SNCA-related genetic risk in sporadic Parkinson disease. Ann Neurol. 2018;84(1):117–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287(19):15345–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501–3.

Article  CAS  PubMed  Google Scholar 

Gima S, Oe K, Nishimura K, Ohgita T, Ito H, Kimura H, et al. Host-to-graft propagation of inoculated alpha-synuclein into transplanted human induced pluripotent stem cell-derived midbrain dopaminergic neurons. Regen Ther. 2024;25:229–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.

Article  PubMed  Google Scholar 

Zampar S, Di Gregorio SE, Grimmer G, Watts JC, Ingelsson M. “Prion-like” seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders. Front Neurosci. 2024;18:1436262.

Article  PubMed  PubMed Central  Google Scholar 

Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs. 2024;38(1):5–22.

Article  CAS  PubMed  Google Scholar 

Alfaidi M, Barker RA, Kuan WL. An update on immune-based alpha-synuclein trials in Parkinson’s disease. J Neurol. 2024;272(1):21.

Article  PubMed  PubMed Central  Google Scholar 

Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, et al. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32(2):211–8.

Article  CAS  PubMed  Google Scholar 

Schofield DJ, Irving L, Calo L, Bogstedt A, Rees G, Nuccitelli A, et al. Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019;132:104582.

Article  CAS  PubMed  Google Scholar 

Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schroder-Hansen LM, et al. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13(1):1994690.

Article  PubMed  PubMed Central  Google Scholar 

Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, et al. Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis. 2019;124:276–88.

Article  CAS  PubMed  Google Scholar 

Nordstrom E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, et al. ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson’s disease. Neurobiol Dis. 2021;161:105543.

Article  PubMed  Google Scholar 

Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387(5):421–32.

Article  CAS  PubMed  Google Scholar 

Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med. 2022;387(5):408–20.

Article  CAS  PubMed  Google Scholar 

Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nat Med. 2024;30(4):1096–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating alpha-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heneka MT, Morgan D, Jessen F. Passive anti-amyloid beta immunotherapy in Alzheimer’s disease-opportunities and challenges. Lancet. 2024;404(10468):2198–208.

Article  CAS  PubMed  Google Scholar 

McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson’s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis. 2024;14(5):899–912.

Article  PubMed  PubMed Central